文献速递慢性肾脏病

卡格列净对肾脏和心血管效应随年龄和性别变化的分析:CREDENCE随机临床试验的事后分析

Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.
PubMed 文献 · Am J Kidney Dis · 2023-03-07

该研究为CREDENCE试验的事后分析,评估卡格列净100mg/d与安慰剂相比,在糖尿病肾病患者中按年龄(<60、60-69、≥70岁)和性别分层的肾脏与心血管结局差异。结果显示卡格列净降低主要复合终点风险在各年龄组和性别间无显著差异(交互作用P分别为0.3和0.8),安全结局无差异。

要点

  • 卡格列净对主要肾脏和心血管复合终点的效应在各年龄组和性别间无显著差异。
  • 年轻参与者因基线风险更高,肾脏不良结局的绝对风险降低幅度更大。
  • 不同年龄组和性别的安全结局无差异。

核心结论

  • 卡格列净在糖尿病肾病患者中一致降低肾脏事件的相对风险,且在男女和各年龄亚组中均一致。
  • 由于年轻参与者基线风险更高,肾脏不良结局的绝对降低幅度在年轻参与者中更大。

研究设计与样本

  • CREDENCE随机对照试验的二次分析,纳入CREDENCE试验参与者。
  • 参与者随机接受卡格列净100mg/d或安慰剂。
  • 在意向治疗人群中,按基线年龄(<60、60-69、≥70岁)和性别分组,使用Cox回归模型评估结局。

主要发现

  • 队列平均年龄63.0±9.2岁,女性占34%。
  • 较年长和女性与肾脏不良复合结局风险较低独立相关。
  • 卡格列净对主要结局(肾衰竭、血清肌酐浓度加倍或肾脏或心血管原因死亡的复合)的效应在年龄组间无差异(HR分别为0.67 [95%CI, 0.52-0.87]、0.63 [0.48-0.82]、0.89 [0.61-1.29] 对应<60、60-69、≥70岁;交互作用P=0.3)。
  • 卡格列净对主要结局的效应在性别间无差异(女性HR 0.71 [95%CI, 0.54-0.95],男性HR 0.69 [0.56-0.84];交互作用P=0.8)。
  • 未观察到安全结局按年龄组或性别的差异。

局限性

  • 此项分析为事后分析,涉及多重比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: It is unclear whether the effect of canagliflozin on adverse kidney and cardiovascular events in those with diabetic kidney disease varies by age and sex. We assessed the effects of canagliflozin among age group categories and between sexes in the Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study. STUDY DESIGN: Secondary analysis of a randomized controlled trial. SETTING & PARTICIPANTS: Participants in the CREDENCE trial. INTERVENTION: Participants were randomly assigned to receive canagliflozin 100mg/d or placebo. OUTCOMES: Primary composite outcome of kidney failure, doubling of serum creatinine concentration, or death due to kidney or cardiovascular disease. Prespecified secondary and safety outcomes were also analyzed. Outcomes were evaluated by age at baseline (<60, 60-69, and≥70 years) and sex in the intention-to-treat population using Cox regression models. RESULTS: The mean age of the cohort was 63.0±9.2 years, and 34% were female. Older age and female sex were independently associated with a lower risk of the composite of adverse kidney outcomes. There was no evidence that the effect of canagliflozin on the primary outcome (a composite of kidney failure, a doubling of serum creatinine concentration, or death from kidney or cardiovascular causes) differed between age groups (HRs, 0.67 [95% CI, 0.52-0.87], 0.63 [0.48-0.82], and 0.89 [0.61-1.29] for ages<60, 60-69, and≥70 years, respectively; P=0.3for interaction) or sexes (HRs, 0.71 [95% CI, 0.54-0.95] and 0.69 [0.56-0.84] in women and men, respectively; P=0.8for interaction). No differences in safety outcomes by age group or sex were observed. LIMITATIONS: This was a post hoc analysis with multiple comparisons. CONCLUSIONS: Canagliflozin consistently reduced the relative risk of kidney events in people with diabetic kidney disease in both sexes and across age subgroups. As a result of greater background risk, the absolute reduction in adverse kidney outcomes was greater in younger participants. FUNDING: This post hoc analysis of the CREDENCE trial was not funded. The CREDENCE study was sponsored by Janssen Research and Development and was conducted collaboratively by the sponsor, an academic-led steering committee, and an academic research organization, George Clinical. TRIAL REGISTRATION: The original CREDENCE trial was registered at ClinicalTrials.gov with study number NCT02065791.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Yi TW, Smyth B, Di Tanna GL, et al. Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial. Am J Kidney Dis. 2023. PMID: 36889425. doi:10.1053/j.ajkd.2022.12.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。